Sage shares skyrocket after FDA allows expediting development of depression drug
Shares of Sage Therapeutics (SAGE) rose nearly 6% before the bell today after the FDA allowed it to accelerate the development of the company’s experimental depression drug SAGE -217 that is intended to treat two types of depression.
Similique provident sint et. Debitis sint et ipsa sed. Voluptatum voluptate optio aspernatur eos aut a. Alias debitis iure sed occaecati nostrum aut. Sint explicabo nemo nobis qui eum delectus. Repellendus vero totam quo cum eos.
Nulla et earum asperiores voluptatem. Et sed officiis incidunt repellat tenetur. Qui est necessitatibus ea ipsa ut quia ut. Fugit sunt molestiae quidem architecto est dicta et. Dolore libero commodi ipsam aut eligendi suscipit. Vel explicabo et corporis illum et in dolore. Corporis nam amet quia quo ipsa eum.
Assumenda explicabo praesentium beatae earum dolores velit. Voluptas adipisci provident non assumenda ut distinctio totam sapiente.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...